There are currently 22 clinical trials in Rialto, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Inland Empire Liver Foundation and Inland Empire Clinical Trials, LLC. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment
NCT05751759
Recruiting
This study will assess the effect of hepatic impairment on the pharmacokinetics (PK), safety and tolerability of mitiperstat.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
04/24/2024
Locations: Research Site, Rialto, California
Conditions: Hepatic Impairment
Register for Updates
ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)
NCT06342947
Recruiting
This is a Phase 2a study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of oral (PO) daily (QD) doses of ALG-055009 (soft gelatin [softgel] capsule) for 12 weeks.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/24/2024
Locations: Aligos Clinical Study Site 10, Rialto, California
Conditions: NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis
Register for Updates
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
NCT04822181
Recruiting
Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. Participants will either get semaglutide or a dummy medicine - which treatment participants get is decided by chance. Participants will need to inject themselves with medicine under the skin. Participants will need to do this once a week. The study will last for about 5 years. Participants will have up to 21 clinic visits a... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Inland Empire Clin Trials LLC, Rialto, California
Conditions: Non-alcoholic Steatohepatitis
Register for Updates
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
NCT03519945
Recruiting
This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Participants who complete the 3-year study may continue to receive mirikizumab until it is (outside of this study) in their country or until they meet other discontinuation criteria.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/16/2024
Locations: Inland Empire Clinical Trials, LLC, Rialto, California
Conditions: Ulcerative Colitis
Register for Updates
A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly
NCT06082843
Recruiting
This study is open to adults with advanced liver cirrhosis caused by hepatitis B, hepatitis C, alcohol-related liver disease, non-alcoholic steatohepatitis or other causes. People can join the study if they have high blood pressure in the portal vein (main vessel going to the liver) and bleeding in the esophagus or fluid accumulation in the belly. The purpose of this study is to find out whether a medicine called avenciguat helps people with this condition. Participants are put into 2 groups by... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/15/2024
Locations: Inland Empire Clinical Trials, LLC, Rialto, California
Conditions: Hypertension, Portal, Liver Cirrhosis
Register for Updates
A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693
NCT05919069
Recruiting
Subcutaneous administration of AZD2693 single dose in participants with hepatic impairment
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/12/2024
Locations: Research Site, Rialto, California
Conditions: Hepatic Impairment
Register for Updates
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection
NCT05763576
Recruiting
This is a first in human (FIH), multi-center, dose-finding, and dose-escalation Phase I clinical study of RO7565020 to investigate the safety and tolerability and to characterize the pharmacokinetics and pharmacodynamics following single and/or multiple doses of RO7565020 in healthy participants and/or virologically suppressed participants with chronic hepatitis B (CHB).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/11/2024
Locations: Inland Empire Liver Foundation, Rialto, California
Conditions: Chronic Hepatitis B
Register for Updates
A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
NCT05809934
Recruiting
A Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 given by subcutaneous injection in adult participants with non-cirrhotic non-alcoholic steatohepatitis with fibrosis and who are carriers of the PNPLA3 148M Risk Allele
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/11/2024
Locations: Research Site, Rialto, California
Conditions: Nonalcoholic Steatohepatitis
Register for Updates
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Non-Alcoholic Steatohepatitis (NASH) in Adult Participants at Increased Genetic Risk for This Condition
NCT05519475
Recruiting
This study is researching an investigational drug called ALN-HSD (called "study drug"). This study is focused on participants who are known to have non-alcoholic steatohepatitis (NASH). NASH is a form of non-alcoholic fatty liver disease (NAFLD). Recently, the name metabolic dysfunction associated steatohepatitis (MASH) has been introduced to replace NASH and metabolic dysfunction-associated steatotic liver disease (MASLD) to replace NAFLD. NASH occurs when fat builds up in liver cells, damaging... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/05/2024
Locations: Inland Empire Liver Foundation, Rialto, California
Conditions: Non-alcoholic Steatohepatitis (NASH), Metabolic Dysfunction Associated Steatohepatitis (MASH)
Register for Updates
Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
NCT03440372
Recruiting
This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/27/2024
Locations: Local Institution - 006, Rialto, California
Conditions: Crohn Disease
Register for Updates
An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
NCT03467958
Recruiting
This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/27/2024
Locations: Local Institution - 006, Rialto, California
Conditions: Crohn Disease
Register for Updates
A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease
NCT05395481
Recruiting
The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3849891 in participants with nonalcoholic fatty liver disease who have the patatin-like phospholipase domain-containing protein 3 (PNPLA3) I148M genotype. Blood tests and magnetic resonance imaging of the liver will be performed to determine the effects of LY3849891 on fatty liver disease. Blood tests will also determine how long it takes the body to eliminate LY3849891. This is a 2-part study and may l... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
03/14/2024
Locations: Inland Empire Clinical Trials, LLC, Rialto, California
Conditions: Non-Alcoholic Fatty Liver Disease
Register for Updates